British artificial intelligence firm announces license agreement with Janssen
Wednesday, November 09, 2016
British artificial intelligence firm announces exclusive license agreement with Janssen for clinical stage drug candidates, facilitated by Johnson & Johnson innovation.
Benevolentai - Will have sole right to develop, manufacture and commercialise novel drug candidates in all indications and in all territories.
Benevolentai - Intends to begin late stage phase IIB clinical trials in mid 2017.
Benevolentai- financial terms were not disclosed.
Source : reuters.com
